Coadministration has not been studied based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Lenacapavir is mainly cleared as unchanged drug and is a moderate inhibitor of CYP3A4 but is unlikely to significantly alter fostemsavir pharmacokinetics.